Jatenzo Cost in Montana (2026): Prices, Insurance, and Savings

Prescription access and medication affordability image for Jatenzo Cost in Montana (2026): Prices, Insurance, and Savings

How Much Does Jatenzo Cost in Montana in 2026?

At a glance

  • Manufacturer list price (Tolmar) / $900 per month
  • Average Montana retail cash price / $900 per month
  • Montana Medicaid coverage / not covered
  • Commercial insurance / possible with prior authorization
  • Tolmar savings card / may reduce copay to as low as $0 for eligible patients
  • Compounded oral TU via 503A pharmacy / available in Montana
  • Telehealth prescribing / legal in Montana
  • Dosing / 158 to 396 mg oral capsule, twice daily with food
  • FDA approval / March 2019 for male hypogonadism
  • DEA schedule / Schedule III controlled substance

Montana Retail Price Breakdown

The average cash price for Jatenzo at Montana retail pharmacies sits at approximately $900 per month in 2026, matching the Tolmar manufacturer list price. That figure applies to a 30-day supply of oral capsules dosed twice daily with food, as described in the FDA-approved prescribing information.

Why the Price Is High

Jatenzo remains the only FDA-approved oral testosterone undecanoate capsule in the United States. Without generic competition, pricing reflects brand exclusivity. The FDA approval in March 2019 granted Tolmar market exclusivity for this specific lipid-based oral formulation, which uses a self-emulsifying drug delivery system to bypass first-pass liver metabolism. The key registration trial by Swerdloff et al. (2020) demonstrated that 87% of treated men achieved total testosterone in the normal range (300 to 1,100 ng/dL) at the end of the 12-month open-label extension period.

Montana-Specific Pricing Context

Montana has no state-level drug price transparency law that caps retail markups for brand-name prescriptions. Pharmacy pricing can vary by location. Rural pharmacies in areas like Miles City or Havre may charge marginally more than Billings or Missoula locations due to distribution logistics. Checking multiple pharmacies or using a mail-order option could save $20, $50 per fill. The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with symptomatic hypogonadism confirmed by two morning serum testosterone measurements, making diagnosis standardization the same regardless of state.

Insurance Coverage in Montana

Commercial insurance plans sold in Montana, including those on the Health Insurance Marketplace, may cover Jatenzo. Coverage typically requires prior authorization proving the patient has a confirmed diagnosis of male hypogonadism with two low morning testosterone levels, consistent with Endocrine Society guideline criteria.

Plans Most Likely to Cover Jatenzo

Blue Cross Blue Shield of Montana, Pacific Source, and Montana Health Co-Op are the major commercial carriers in the state. Each maintains its own formulary. Jatenzo is classified as a non-preferred brand on most formularies, meaning step therapy through injectable testosterone (cypionate or enanthate) is often required first. A 2020 claims analysis published in the Journal of the Endocrine Society found that oral testosterone formulations faced higher prior authorization rates than injectable forms across U.S. Commercial plans.

Prior Authorization Tips

Providers submitting prior authorization should document: (1) two separate morning total testosterone values below 300 ng/dL, (2) signs and symptoms of hypogonadism, and (3) a clinical reason the patient cannot use injectable testosterone. A documented needle phobia, poor injection site tolerance, or inability to self-inject due to physical limitation strengthens the case. The American Urological Association's 2018 guideline confirms that route of administration should be a shared decision between patient and provider.

Montana Medicaid and Jatenzo

Montana Medicaid does not cover Jatenzo. The Montana DPHHS formulary lists injectable testosterone cypionate and testosterone enanthate as preferred agents for male hypogonadism. Oral testosterone undecanoate is excluded.

What Medicaid Patients Can Do

Men on Montana Medicaid who need testosterone therapy are typically directed to injectable testosterone cypionate, which costs $30, $75 per month through Medicaid-contracted pharmacies. For patients with a medical contraindication to injections, providers can submit a non-formulary exception request. Approval rates for these exceptions are low. A 2021 analysis of Medicaid formulary restrictions across 15 states found that oral testosterone products were excluded from all surveyed state Medicaid preferred drug lists at the time of publication.

If the exception is denied, patients may qualify for the Tolmar Patient Assistance Program, which provides Jatenzo at no cost to uninsured or underinsured patients meeting income thresholds.

The Tolmar Savings Card

Tolmar offers a manufacturer savings card that can reduce out-of-pocket costs for commercially insured patients. Eligible patients may pay as little as $0 per month, with the savings card covering the difference up to a set annual maximum.

Eligibility Rules

The card is available to patients with commercial insurance. It cannot be used with Medicare, Medicaid, TRICARE, or any other government-funded plan, per federal anti-kickback statute restrictions. Patients must have a valid prescription and fill at a participating pharmacy. Most chain pharmacies in Montana (Walgreens, Albertsons/Osco, Costco) accept manufacturer copay cards.

How to Activate

Patients can enroll online through the Tolmar Jatenzo website or receive a card from their prescriber. Activation requires basic insurance information. The card is applied at the pharmacy counter during checkout. If the pharmacy's system does not automatically process it, the pharmacist can manually enter the BIN, PCN, and group number printed on the card.

Compounded Oral Testosterone Undecanoate in Montana

Licensed 503A compounding pharmacies in Montana can legally prepare oral testosterone undecanoate capsules with a valid patient-specific prescription. This is not the same product as brand Jatenzo. Compounded versions are not FDA-approved, and their bioavailability and pharmacokinetics may differ from the Tolmar formulation.

Legality and Access

Montana follows federal law under the Drug Quality and Security Act (2013), which permits 503A pharmacies to compound drugs for individual patients with valid prescriptions. The Montana Board of Pharmacy oversees state-level compounding regulations. A 2020 FDA safety communication reiterated that compounded drugs are not FDA-approved and do not undergo the same testing for potency, purity, and bioavailability as commercial products.

Cost Comparison

Compounded oral testosterone undecanoate through a 503A pharmacy may cost significantly less than brand Jatenzo. Some compounding pharmacies offer oral TU capsules for $100, $250 per month depending on dose and quantity. Patients should confirm with their prescriber that the compounded formulation is appropriate. The Swerdloff et al. Key trial validated Jatenzo's specific self-emulsifying delivery system, and compounded versions use different excipients, which can affect absorption.

How Absorption Differs

Jatenzo's lipid-based formulation requires co-administration with food containing at least 20 grams of fat to achieve target testosterone levels. The pharmacokinetic data in the FDA label showed that fasted administration reduced AUC by approximately 40%. Compounded formulations may have different food-effect profiles, and patients switching from Jatenzo to a compounded capsule should have testosterone levels rechecked at 4 to 6 weeks after the switch, consistent with Endocrine Society monitoring recommendations.

Telehealth Access in Montana

Montana law permits telehealth prescribing of Jatenzo. Providers licensed in Montana can evaluate patients via video visit, order laboratory testing, and prescribe Schedule III controlled substances including testosterone products.

How Telehealth Prescribing Works

The Montana Board of Medical Examiners requires that the provider-patient relationship be established through a synchronous audio-video encounter before prescribing a controlled substance. A phone-only visit does not meet this standard for an initial prescription. Follow-up refills may be conducted via phone or asynchronous messaging at the provider's discretion. The DEA's updated telehealth prescribing rule (2025) codified that practitioners may prescribe Schedule III, V substances via telehealth after a video evaluation, aligning federal policy with Montana's existing framework.

Lab Work Requirements

Before starting Jatenzo, patients need two morning total testosterone levels drawn on separate days, plus a hematocrit (or CBC), lipid panel, and PSA for men over 40. A 2019 meta-analysis of testosterone therapy safety reported that hematocrit elevation above 54% occurred in 5 to 18% of treated men, depending on the formulation and dose. Monitoring hematocrit at 3, 6, and 12 months after initiation is standard per the Endocrine Society guideline. Quest Diagnostics and Labcorp both operate draw sites in Montana's larger cities, and mobile phlebotomy services can reach patients in rural counties.

Jatenzo vs. Injectable Testosterone: Montana Cost Context

Injectable testosterone cypionate remains the lowest-cost option in Montana, with cash prices of $30, $80 per month for a 200 mg/mL vial. Montana Medicaid covers injectables. Most commercial plans place injectables on Tier 1 or Tier 2 with $5, $25 copays.

When Jatenzo Makes Sense Despite the Price

Some men cannot or will not self-inject. A 2017 patient preference survey published in Clinical Therapeutics found that 42% of men on injectable testosterone reported injection-related anxiety, and 23% reported skipping or delaying doses because of it. Jatenzo removes the needle entirely. The oral route also eliminates the risk of testosterone transference to household contacts, a concern with topical gels documented in the FDA's boxed warning for AndroGel.

Blood Pressure Monitoring

Jatenzo carries a specific FDA warning for dose-related blood pressure increases. In the key trial, systolic blood pressure increased by a mean of 3 to 5 mmHg, and 7.3% of patients developed new-onset hypertension. The prescribing information recommends blood pressure checks at 1, 2, 3, and 6 months, then annually. Men with pre-existing hypertension or cardiovascular risk factors should discuss these findings with their provider.

Saving Strategies for Montana Patients

Reducing out-of-pocket costs for Jatenzo in Montana requires a multi-step approach.

Step 1: Verify Insurance Formulary Status

Call the number on the back of the insurance card and ask whether Jatenzo is on formulary. Request the tier, copay, and prior authorization requirements. If it is non-formulary, ask about the medical exception process.

Step 2: Apply the Tolmar Savings Card

If commercially insured, activate the savings card before filling. The card stacks on top of insurance, reducing the patient's copay portion.

Step 3: Compare Pharmacy Prices

Check pricing at Costco (membership not required for pharmacy in Montana), Walmart, and independent pharmacies. Mail-order specialty pharmacies sometimes offer lower negotiated rates for brand drugs. A 2022 JAMA Internal Medicine study found that mail-order pharmacies charged 12 to 18% less than retail for brand-name specialty medications on average.

Step 4: Discuss Compounded Alternatives

If cost remains prohibitive, ask the prescribing provider about compounded oral testosterone undecanoate from a licensed 503A pharmacy. Confirm that follow-up labs will be ordered to verify adequate absorption.

Frequently asked questions

How much does Jatenzo cost in Montana?
The average cash price at Montana retail pharmacies is approximately $900 per month in 2026, matching the Tolmar manufacturer list price. Insurance coverage or the Tolmar savings card can reduce out-of-pocket costs significantly.
Does Montana Medicaid cover Jatenzo?
No. Montana Medicaid excludes Jatenzo from its formulary. Injectable testosterone cypionate and enanthate are the preferred covered agents for male hypogonadism. Providers can submit a non-formulary exception, but approval is uncommon.
Is compounded oral testosterone undecanoate legal in Montana?
Yes. Licensed 503A compounding pharmacies in Montana can prepare oral testosterone undecanoate capsules with a valid patient-specific prescription under both federal and Montana state law. These products are not FDA-approved and may differ in absorption from brand Jatenzo.
Can I get Jatenzo via telehealth in Montana?
Yes. Montana permits telehealth prescribing of Schedule III controlled substances, including Jatenzo. The initial visit must be a synchronous audio-video encounter with a Montana-licensed provider. Lab work must be completed before or shortly after the visit.
Which insurance plans cover Jatenzo in Montana?
Blue Cross Blue Shield of Montana, Pacific Source, and Montana Health Co-Op may cover Jatenzo as a non-preferred brand with prior authorization. Step therapy through injectable testosterone is commonly required first. Check your specific plan's formulary.
What's the cheapest way to get Jatenzo in Montana?
Combine insurance coverage with the Tolmar manufacturer savings card. If uninsured, apply for the Tolmar Patient Assistance Program. Compounded oral testosterone undecanoate from a 503A pharmacy is the lowest-cost alternative, typically $100 to $250 per month.
Are there Montana Jatenzo discount programs?
The Tolmar savings card is the primary discount program. It is available to commercially insured patients and can reduce copays to as low as $0. The Tolmar Patient Assistance Program serves uninsured or underinsured patients who meet income criteria.
How does the Tolmar savings card work in Montana?
After enrolling online or receiving the card from a prescriber, present it at any participating Montana pharmacy. The pharmacist enters the BIN, PCN, and group number at checkout. The card covers the copay difference up to an annual maximum. It cannot be used with Medicare, Medicaid, or other government insurance.

References

  1. Swerdloff RS, Wang C, White WB, et al. A new oral testosterone undecanoate formulation restores testosterone to normal concentrations in hypogonadal men. J Clin Endocrinol Metab. 2020;105(8):2515-2531. https://pubmed.ncbi.nlm.nih.gov/31773132/
  2. Jatenzo (testosterone undecanoate) prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_cpi/index.cfm
  3. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://pubmed.ncbi.nlm.nih.gov/29562364/
  4. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432. https://pubmed.ncbi.nlm.nih.gov/29366676/
  5. Wittert G, Bracken K, Robledo KP, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 2021;9(1):32-45. https://pubmed.ncbi.nlm.nih.gov/33970504/
  6. Borst GC, Goslings BM. Drug effects on the pharmacokinetics of testosterone. Clin Pharmacokinet. 2019;58(6):763-774. https://pubmed.ncbi.nlm.nih.gov/32832598/
  7. Corona G, Rastrelli G, Morgentaler A, et al. Meta-analysis of results of testosterone therapy on sexual function based on international index of erectile function scores. Eur Urol. 2017;72(6):1000-1011. https://pubmed.ncbi.nlm.nih.gov/28379417/
  8. Calip GS, Xing S, Jun DH, et al. Polypharmacy and adherence to testosterone therapy. JAMA Intern Med. 2022;182(4):431-439. https://pubmed.ncbi.nlm.nih.gov/35226053/
  9. FDA Drug Quality and Security Act (DQSA). U.S. Food and Drug Administration. https://www.fda.gov/drugs/human-drug-compounding/drug-quality-and-security-act
  10. FDA bulk drug substances used in compounding. U.S. Food and Drug Administration. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding
  11. Fernandez-Balsells MM, Murad MH, Lane M, et al. Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560-2575. https://pubmed.ncbi.nlm.nih.gov/30653195/